Concomitant Left Atrial Appendage Closure DRG 317 Reimbursement

DRG 317 addresses inpatient admissions for concomitant left atrial appendage closure and cardiac ablation, encompassing procedural and perioperative care for atrial fibrillation and stroke risk reduction. This classification matters for inpatient reimbursement because it consolidates resource use for two significant cardiac procedures into one Diagnosis-Related Group, influencing payment, documentation, and coding requirements under Medicare.

DRG 317 Overview

DRG 317 covers hospital inpatient admissions for patients who undergo concomitant left atrial appendage closure and cardiac ablation, procedures commonly performed for atrial fibrillation management and stroke risk reduction. This Diagnosis-Related Group groups the resource use and clinical complexity of combining a structural heart intervention with an electrophysiology procedure. It matters for Medicare payment because bundling both procedures into a single inpatient episode affects reimbursement relative to standalone procedures and reflects the combined procedural, monitoring, and complication-management resources required. Payer classification under this Diagnosis-Related Group impacts hospital billing, coding specificity, and case-mix considerations.

Randomized controlled comparative effectiveness trials of concomitant left atrial appendage (LAA) closure plus catheter ablation versus catheter ablation alone for patients with atrial fibrillation and elevated stroke risk. These studies enroll adult patients with nonvalvular atrial fibrillation who are candidates for rhythm-control ablation and have CHA2DS2-VASc scores indicating need for stroke prevention; endpoints include periprocedural safety, recurrence of atrial fibrillation, ischemic stroke, and need for long-term oral anticoagulation. This research directly informs inpatient procedural decision-making and resource use by clarifying whether adding LAA closure at the index ablation reduces downstream stroke events or anticoagulation-related complications relevant to providers and payers.
Prospective observational registries and real-world safety studies focusing on perioperative and short-term complications when LAA closure and ablation are performed concomitantly, including bleeding, cardiac tamponade, vascular complications, and readmissions. These registries typically capture a broader, more comorbid inpatient population than randomized trials (older patients, those with heart failure, renal impairment, prior stroke), tracking device- or procedure-related adverse events, length of stay, and need for reintervention. Such data help hospitals, clinicians, and payers assess expected complication rates, LOS variability, and cost drivers for accurate DRG utilization, benchmarking, and quality improvement.
Longitudinal outcomes and cost-effectiveness studies assessing post-discharge outcomes such as long-term stroke incidence, sustained freedom from atrial fibrillation, anticoagulant discontinuation rates, quality of life, and total healthcare costs over multiple years. These cohort studies or decision-analytic models evaluate whether upfront combined procedures translate into reduced long-term morbidity, lower readmission rates, and net savings or increased costs to payers given device/procedure expenses versus avoided strokes and bleeding events. Results are important for payers and hospital systems to align reimbursement strategies, post-acute care planning, and value-based care initiatives for patients categorized under this DRG.

Randomized controlled comparative effectiveness trials of concomitant left atrial appendage (LAA) closure plus catheter ablation versus catheter ablation alone for patients with atrial fibrillation and elevated stroke risk. These studies enroll adult patients with nonvalvular atrial fibrillation who are candidates for rhythm-control ablation and have CHA2DS2-VASc scores indicating need for stroke prevention; endpoints include periprocedural safety, recurrence of atrial fibrillation, ischemic stroke, and need for long-term oral anticoagulation. This research directly informs inpatient procedural decision-making and resource use by clarifying whether adding LAA closure at the index ablation reduces downstream stroke events or anticoagulation-related complications relevant to providers and payers.
Prospective observational registries and real-world safety studies focusing on perioperative and short-term complications when LAA closure and ablation are performed concomitantly, including bleeding, cardiac tamponade, vascular complications, and readmissions. These registries typically capture a broader, more comorbid inpatient population than randomized trials (older patients, those with heart failure, renal impairment, prior stroke), tracking device- or procedure-related adverse events, length of stay, and need for reintervention. Such data help hospitals, clinicians, and payers assess expected complication rates, LOS variability, and cost drivers for accurate DRG utilization, benchmarking, and quality improvement.
Longitudinal outcomes and cost-effectiveness studies assessing post-discharge outcomes such as long-term stroke incidence, sustained freedom from atrial fibrillation, anticoagulant discontinuation rates, quality of life, and total healthcare costs over multiple years. These cohort studies or decision-analytic models evaluate whether upfront combined procedures translate into reduced long-term morbidity, lower readmission rates, and net savings or increased costs to payers given device/procedure expenses versus avoided strokes and bleeding events. Results are important for payers and hospital systems to align reimbursement strategies, post-acute care planning, and value-based care initiatives for patients categorized under this DRG.

OpenPayer

Summary & Overview

Concomitant Left Atrial Appendage Closure and Cardiac Ablation: Inpatient Reimbursement Overview

DRG 317 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes